Pathogenesis of myeloma, Annu Rev Pathol, vol.6, pp.249-274, 2011. ,
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma, Blood, vol.106, pp.296-303, 2005. ,
Molecular pathogenesis of multiple myeloma: basic and clinical updates, Int J Hematol, vol.97, pp.313-323, 2013. ,
G1 cell-cycle control and cancer, Nature, vol.432, pp.298-306, 2004. ,
Cyclin D as a therapeutic target in cancer, Nat Rev Cancer, vol.11, pp.558-572, 2011. ,
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation, Blood, vol.102, pp.1588-1594, 2003. ,
Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway, BMC Cancer, vol.15, pp.262-273, 2015. ,
,
, Cyclin D1 governs adhesion and motility of macrophages, Mol Biol Cell, vol.14, pp.2005-2015, 2003.
Cyclin D1 induction of cellular migration requires p27 KIP1, Cancer Res, vol.66, pp.9986-9994, 2006. ,
Alternate Cyclin D1 mRNA splicing modulates p27 KIP1 binding and cell migration, J Biol Chem, vol.283, pp.7007-7015, 2008. ,
Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells, Cancer Res, vol.70, pp.2105-2114, 2010. ,
Cyclin D1 localizes in the cytoplasm of keratinocytes during skin differentiation and regulates cell-matrix adhesion, Cell Cycle, vol.12, pp.2510-2517, 2013. ,
Therapeutic advancements in multiple myeloma, Front Oncol, vol.4, pp.1-5, 2014. ,
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitinproteasome pathway, against preclinical models of multiple myeloma, Blood, vol.110, pp.3281-3290, 2007. ,
New strategies in the treatment of multiple myeloma, Clin Cancer Res, vol.19, pp.3337-3344, 2013. ,
Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines, Blood, vol.93, pp.1658-1567, 1999. ,
Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-?B (RelB/p50) in myeloma cells, Oncogene, vol.22, pp.2417-2421, 2003. ,
Adhesion to fibronectin induces p27 Kip1 nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesionmediated drug resistance (CAM-DR) in RPMI 8,226 cells, Mol Cell Biol, vol.386, pp.177-187, 2013. ,
Adhesion to fibronectin via ?1 integrins regulates p27 kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR), Oncogene, vol.19, pp.4319-4327, 2000. ,
Bortezomib overcomes cell adhesionmediated drug resistance through downregulation of VLA-4 expression in multiple myeloma, Oncogene, vol.28, pp.231-242, 2008. ,
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules, Exp Hematol, vol.41, pp.387-397, 2013. ,
Redox regulation of cell adhesion and migration, Trends Cell Biol, vol.22, pp.107-115, 2012. ,
Redox regulation and its emerging roles in stem cells and stem-like cancer cells, Antioxid Redox Signal, vol.11, pp.1107-1122, 2009. ,
Cyclin D1 determines mitochondrial function in vivo, Mol Cell Biol, vol.26, pp.5449-5469, 2006. ,
Cyclin D1 inhibits mitochondrial activity in B cells, Cancer Res, vol.71, pp.1690-1699, 2011. ,
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases, Leukemia, vol.25, pp.281-289, 2011. ,
The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma, Blood Cancer J, vol.4, pp.229-213, 2014. ,
Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib, Br J Haematol, vol.14, pp.494-503, 2008. ,
Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity, Apoptosis, vol.11, pp.2225-2235, 2006. ,
Targeting the bone marrow environment in mutiple myeloma, Immunol Rev, vol.263, pp.160-172, 2015. ,
Integrin ?7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion, Blood, vol.117, pp.6202-6213, 2011. ,
PACSIN 2 represses cellular migration through direct association with cyclin D1 but not its alternate splice form cyclin D1b, Cell Cycle, vol.10, pp.73-81, 2011. ,
Sorafenib inhibits cell migration and stroma-mediated bortezomib-resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma, Clin Cancer Res, vol.19, pp.586-597, 2013. ,
Cyclin D1 interacts and collaborates with Ral GTPases cell detachment an motility, Oncogene, vol.30, pp.1936-1946, 2011. ,
Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells, Cell Death Disease, vol.3, p.446, 2012. ,
Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma, Oncotarget, vol.6, pp.15410-15424, 2015. ,
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor, Clin Cancer Res, vol.10, pp.3839-3852, 2004. ,
Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death, Blood, vol.123, pp.2997-3006, 2014. ,
Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells, Leukemia, vol.30, pp.104-111, 2016. ,
The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology, Physiol Rev, vol.87, pp.245-313, 2007. ,
Occurence of cytochrome b558 in B-cell lineage of human lymphocytes, Blood, vol.75, pp.458-461, 1990. ,
Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway, Blood, vol.119, pp.3523-3553, 2012. ,
Synergistic activity of carfilzomib and panobinostat in multiple myeloma cells via modulation of ROS generation and ERK1/2, Biomed Res Int, p.459052, 2015. ,
MEK inhibitors as a chemotherapeutic intervention in multiple myeloma, Blood Cancer J, vol.3, p.105, 2013. ,
Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma, J Cell Biochem, vol.113, pp.419-425, 2012. ,
PRIMA-1 Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance, Blood, vol.124, pp.1626-1636, 2014. ,
Targeting MUC1-C is synergisticc with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death, Blood, vol.123, pp.2997-3006, 2014. ,